ClinicalTrials.gg
CompletedNCT00161655Updated Sep 28, 2009

Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis

A Phase 4 interventional study of Etanercept and Methotrexate in Psoriasis and Arthritis, Psoriatic, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 8 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-09-28.

Primary conditionArthritis, PsoriaticRegistry: PsoriasisReclassifiedWhy we changed it
Registry
Psoriasis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Arthritis, Psoriatic
Why
  1. The study's listed conditions name Arthritis, Psoriatic, a narrower term within Psoriasis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 14 studies testing etanercept in Arthritis, Psoriatic — 2 open to participants now, 2 under way, 1 of them phase 3. Etanercept · Arthritis, Psoriatic.

Enrollment
11th of 14
60 · median 105
Started
2005
with 3 others
Phase 4
6 of 14
none open now
Registered
2nd of 14
by date
Lead sponsor
2 of 14
Wyeth is now a wholly owned subsidiary of Pfizer

Among the 14 studies testing etanercept in Arthritis, Psoriatic, this one is the 11th largest by enrollment, is one of 4 that started in 2005, is one of 6 in phase 4, and was the 2nd registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

2 of the 14 studies testing etanercept in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About etanercept

Etanercept: first FDA approval 1998 (ENBREL), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Arthritis, Psoriatic studies recruiting now, 52 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing etanercept in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy to clear or almost clear the plaques in plaque psoriasis patients, treated with the combination etanercept and methotrexate compared to etanercept alone.

03

Conditions studied

  • Psoriasis
  • Arthritis, Psoriatic

Browse trials for

Keywords

  • Psoriasis
  • Arthritis
04

In context

Arthritis, Psoriatic Reclassified

601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.

This study's enrollment of 60 is below the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.

Browse Arthritis, Psoriatic studies →

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.

First submitted before Wyeth became part of Pfizer.

Compared within Arthritis, Psoriatic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Psoriasis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Active plaque psoriasis involving >10% body surface area and/or minimal screening PASI score 8.
  • Methotrexate >7.5 mg/week for the last 3 months

Exclusion criteria

Exclusion Criteria:

  • Predominantly guttate, erythrodermic or pustular psoriasis
  • Other skin conditions than psoriasis
06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants

Interventions

07

What researchers measure

Primary outcomes

  1. Proportion of pts whose plaque psoriasis is cleared or almost cleared after 24 weeks.

Secondary outcomes

  1. Percentage improvement in PASI. Proportion of pts demonstrating PASI 50, 75

  2. and 90. Time to clear or almost clear on PGA.

08

Study locations

8 sites
  • Fredriksberg Alle, Copenhagen, Denmark
  • Gentofte Amtsygehus, Hellerup, Denmark
  • Helsinki, Finland
  • Tampere, Finland
  • Rikshospitalet, Olso, Norway
  • Hudlegekontoret Akutten, Tromso, Norway
  • Lakarhuset Fasta Centrum, Farsta, Sweden
  • Lakarhuset, Vallingby, Sweden
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2005, a primary completion of Aug 2006 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2005
First posted
Sep 12, 2005
Start
Apr 2005
Primary completionActual
Aug 2006
CompletionActual
Dec 2006
Last update
Sep 28, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00161655
First posted
Sep 12, 2005
Start date
Apr 2005
Primary completion
Aug 2006
Completion
Dec 2006
Last update
Sep 28, 2009

Study contacts

Medical Monitor
study director · Wyeth is now a wholly owned subsidiary of Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Etanercept · Methotrexate

Start the discussion